What Is Known About Cell-Based Therapy for Degenerative Disc Disease?
Published November 16, 2026
Protocol: 7 steps in this guide
The evidence points in two directions. A 2026 meta-analysis of seven randomized trials found modestly greater reductions in back pain and disability with stem cell injections into the disc than with sham or placebo. But a carefully designed sham-controlled trial, DREAM, found that pain, disability and quality of life improved just as much with a sham procedure as with stem cells over six months, even though some MRI measures changed. Both results matter, and neither shows that cell injections reliably reverse disc degeneration or that they are an approved treatment.
Disc degeneration on imaging versus the cause of pain
A disc that looks worn on MRI is one possible pain source among several structures in the spine, which is why trials try to exclude other causes. A 2024 multispecialty guideline in the Journal of Pain Research, Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain, notes that several structures within the disc, “including the annulus fibrosis, the nucleus pulposus, and the cartilaginous endplates,” can contribute to discogenic pain. The trials discussed here enrolled people whose chronic low back pain had not responded to conservative care and whose discs showed degeneration. DREAM, for example, excluded people with spinal deformity, infection, symptomatic facet joint syndrome, spinal stenosis, instability, disc herniation with sciatica, endplate abnormalities and certain Modic changes.
Intradiscal delivery
In these trials, cells are injected into the disc itself, an intradiscal injection, which is different from an epidural injection into the space around the nerves. In the DREAM trial, the cells were the patient’s own bone marrow stromal cells, which required a bone marrow harvest under conscious sedation, then laboratory processing, then injection into up to three lumbar discs. The cells themselves are explained in what mesenchymal stromal cells are.
The pooled evidence
A 2026 systematic review and meta-analysis in the Asian Spine Journal, Intradiscal mesenchymal stem cell therapy for degenerative disc disease, included seven randomized trials comparing intradiscal stem cell injections with sham or placebo, with searches up to April 30, 2025. It reported:
- greater reductions in VAS pain scores with stem cells than with sham or placebo;
- a greater reduction in the Oswestry Disability Index, a mean difference of about 4 percentage points;
- no significant differences in adverse events, serious adverse events, discontinuation due to adverse events, or deaths.
It concluded that intradiscal stem cell injection “appears to be a safe and effective therapy, offering modest improvements in pain and function” for people with chronic low back pain from disc degeneration who have not responded to conservative treatment. The word “modest” is the review’s own.
The DREAM trial: no advantage over sham
The DREAM study, by VadalĂ and colleagues in JOR Spine (2025), is described in its title as a preliminary report of a double-blind, phase IIB randomized clinical trial. Its key facts:
| Feature | Detail |
|---|---|
| Patients | 52 with chronic low back pain and moderate-to-advanced degeneration at up to three lumbar levels |
| Comparison | Autologous bone marrow stromal cells versus a sham procedure |
| Completed 6 months | 46 (21 cell group, 25 sham group) |
| Clinical result | VAS, ODI and SF-36 "improved similarly in both groups without significant intergroup differences at any timepoint" |
| Imaging result | Significant increase in disc height index; a transient improvement in Pfirrmann grade (an MRI grading of disc degeneration) at 3 months that returned to baseline at 6 months |
The authors concluded that “no significant clinical advantages over the sham procedure were observed within 6 months of follow-up.” The sham group showed slightly greater improvement in disability and physical quality-of-life scores.
Why the two results can both be true
The pooled review and DREAM are not necessarily in conflict. A pooled analysis can detect a small average effect across trials that differ in cell type, dose, patient selection and length of follow-up. DREAM was small and followed patients for six months; its authors note that a sham procedure “might induce a placebo response,” and cite another trial that found significant improvement versus placebo only after 12 months. DREAM’s message is that, under a strong sham control, a clear clinical advantage did not appear within six months. The two should be weighed together, with the review’s own word “modest” kept in view. Why sham controls matter is explained in the difference between a placebo-controlled trial and an observational study.
Exclusions, attrition and procedural risk
DREAM shows how many steps can go wrong before an injection. In the cell group, three patients were excluded because their harvested cells showed karyotype alterations, meaning chromosomal changes, and one because of bone marrow contamination; two patients, one per group, were lost to follow-up. Safety monitoring covered “infection, bleeding, and nerve injury with potential permanent damage,” and the trial reported no cases of bleeding, infection or death; serious adverse events occurred in 4 people in the cell group and 3 in the sham group. Any needle placed into a disc carries procedural risk, and a cell product adds harvest and manufacturing steps. FDA’s patient and consumer information on regenerative medicine therapies lists bacterial infections among safety concerns with illegally marketed regenerative products.
Structural MRI versus disability
DREAM is a clear example of imaging and symptoms moving separately: disc height increased in the cell group, yet patients did not feel or function better than those who had a sham procedure. An MRI change is not the same as a clinical benefit, as discussed in why pain scores can improve without cartilage regrowth on MRI. FDA’s patient notice states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition,” listing disc disease and back pain among the examples. How cell products are regulated is covered in how the FDA regulates stem cell products promoted for joint pain, and long-term safety tracking in how researchers monitor long-term safety after cell therapy.
Cell-based therapy for degenerative disc disease shows modest pooled benefits in pain and disability, but a well-controlled sham trial found no clinical advantage at six months despite imaging changes, so it remains an investigational treatment that is not FDA-approved and not proven to reverse disc degeneration.
Cells linked to this one
This guide leads on to
- E2 What Are Mesenchymal Stromal Cells (MSCs)?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- I10 Why Can Pain Scores Improve Without Cartilage Regrowth on MRI?
- F11 How Does the FDA Regulate Stem Cell Products Promoted for Joint Pain?
- I6 How Do Researchers Monitor Long-Term Safety After Cell Therapy?
Add a remark